Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Feb 26, 2024; 16(2): 64-66
Published online Feb 26, 2024. doi: 10.4330/wjc.v16.i2.64
Facing ethical concerns in the age of precise gene therapy: Outlook on inherited arrhythmias
Federico Carbone, Fabrizio Montecucco
Federico Carbone, Fabrizio Montecucco, Department of Internal Medicine, University of Genoa, Genoa 16132, Italy
Federico Carbone, Fabrizio Montecucco, IRCCS Ospedale Policlinico San Martino Genoa, Italian Cardiovascular Network, Genoa 16132, Italy
Author contributions: Carbone F and Montecucco F performed research and wrote the paper.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fabrizio Montecucco, MD, PhD, Full Professor, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genova, Italy. fabrizio.montecucco@unige.it
Received: November 30, 2023
Peer-review started: November 30, 2023
First decision: December 28, 2023
Revised: January 2, 2024
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: February 26, 2024
Core Tip

Core Tip: As for other diseases, inherited arrhythmias may take advantage from gene editing. Even we are still far from clinical translation, ethical issues need to be considered in order to proceed in this research field avoiding any misconduct. Off-target effects, equitable accessibility of life-saving gene therapies and economic burden for healthcare systems are key issues that need to addressed by regulatory entities.